February 26, 2001

Should New Drugs Be Used Without Outcome Data?Implications of ALLHAT and ELITE II

Author Affiliations

Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2001

Arch Intern Med. 2001;161(4):511-512. doi:10.1001/archinte.161.4.511

AS THE most common disease encountered by medical practitioners, hypertension continues to attract new therapies that promise greater efficacy and fewer adverse effects than currently available drugs. The most recently introduced new class of antihypertensive drugs, the angiotensin II receptor blockers (ARBs), is the fastest-growing group, having been prescribed in the United States more than 23 million times in 1999, only a few years after their introduction. With 6 ARBs now available, and more likely on the way, they are widely touted as a major advance, in part because of their tolerability.1,2

First Page Preview View Large
First page PDF preview
First page PDF preview